Free Trial
→ The Trump Dump is starting; Get out of stocks now? (From Paradigm Press) (Ad)
NASDAQ:ONCO

Onconetix 10/20/2023 Earnings Report

Onconetix logo
$0.07 +0.00 (+3.89%)
As of 11:38 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Earnings History

Onconetix EPS Results

Actual EPS
-$17.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Onconetix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Onconetix Announcement Details

Quarter
Date
10/20/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Onconetix's next earnings date is estimated for Monday, May 19, 2025, based on past reporting schedules.

Conference Call Resources

Onconetix Earnings Headlines

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
April 30, 2025 | globenewswire.com
Onconetix faces third delisting threat since 2022 IPO
April 21, 2025 | bizjournals.com
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
May 7, 2025 | Timothy Sykes (Ad)
Onconetix Inks Letter Of Intent For Potential Business Combination With Ocuvex
April 10, 2025 | nasdaq.com
Five things you need to know today, and calming irrational fears
April 9, 2025 | bizjournals.com
Onconetix signs non-binding LOI for potential combination with Ocuvex
April 9, 2025 | markets.businessinsider.com
See More Onconetix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Onconetix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Onconetix and other key companies, straight to your email.

About Onconetix

Onconetix (NASDAQ:ONCO), a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

View Onconetix Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles